Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates. Novartis will then potentially move candidates forward through the clinic, according to a Nov. 20 release.